Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin

Planta Medica

Volumn 78, Issue 16, 2012, Pages 1740-1748

  Yao, Xiangyang ^a   Li, Guilan ^b   Xu, Hui ^a   Lü, Chaotian ^a  

^a BENGBU COLLEGE   (China)

^b NANJING NORMAL UNIVERSITY   (China)

Author keywords

Aphyllophoromycetideae; chemosensitivity; cisplatin; ganoderic acid A; Ganoderma lucidum; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GANODERIC ACID A; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; STAT3 PROTEIN; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRAIN HEPG2; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL NUCLEUS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENES, REPORTER; HEP G2 CELLS; HEPTANOIC ACIDS; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; LANOSTEROL; LUCIFERASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

GANODERMA LUCIDUM;

EID: 84868624596     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1315303     Document Type: Article

References (46)

1. Yuen J. W., Gohel M. D. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer: 2005; 53 11 17 (Pubitemid 43068549)
2. Zhu M., Chang Q., Wong L. K., Chong F. S., Li R. C. Triterpene antioxidants from Ganoderma lucidum. Phytother Res: 1999; 13 529 531 (Pubitemid 29445775)
3. Jiang J., Grieb B., Thyagarajan A., Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med: 2008; 21 577 584
4. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol: 2007; 7 41 51 (Pubitemid 46020826)
5. Aggarwal B. B., Kunnumakkara A. B., Harikumar K. B., Gupta S. R., Tharakan S. T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci: 2009; 1171 59 76
6. Yu H., Jove R. The STATs of cancernew molecular targets come of age. Nat Rev Cancer: 2004; 4 97 105 (Pubitemid 38198738)
7. Reich N. C., Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol: 2006; 6 602 612 (Pubitemid 44134093)
8. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer: 2009; 9 798 809
9. Catlett-Falcone R., Landowski T. H., Oshiro M. M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J. L., Nunez G., Dalton W. S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity: 1999; 10 105 115 (Pubitemid 29077388)
10. Al Zaid Siddiquee K., Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res: 2008; 18 254 267 (Pubitemid 351206162)
11. Yang C. F., Shen H. M., Ong C. N. Protective effect of ebselen against hydrogen peroxide-induced cytotoxicity and DNA damage in HepG2 cells. Biochem Pharmacol: 1999; 57 273 279
12. Shi R. X., Ong C. N., Shen H. M. Protein kinase c inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factorrelated apoptosis-inducing ligandinduced apoptosis in cancer cells. Cancer Res: 2005; 65 7815 7823
13. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene: 2000; 19 2474 2488 (Pubitemid 30339203)
14. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J. S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature: 1996; 379 645 648 (Pubitemid 26053453)
15. Darnell J. E. Jr., Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science: 1994; 264 1415 1421 (Pubitemid 24217131)
16. Decker T., Kovarik P. Serine phosphorylation of STATs. Oncogene: 2000; 19 2628 2637 (Pubitemid 30339219)
17. Chen R. H., Chang M. C., Su Y. H., Tsai Y. T., Kuo M. L. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem: 1999; 274 23013 23019
18. Han Y., Amin H. M., Franko B., Frantz C., Shi X., Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood: 2006; 108 2796 2803
19. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer: 2007; 7 573 584 (Pubitemid 47106628)
20. Lee H., Herrmann A., Deng J. H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D. M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell: 2009; 15 283 293
21. Hu H., Ahn N. S., Yang X., Lee Y. S., Kang K. S. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer: 2002; 102 250 253 (Pubitemid 35222292)
22. Dudhgaonkar S., Thyagarajan A., Sliva D. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol: 2009; 9 1272 1280
23. Chanvorachote P., Pongrakhananon V., Wannachaiyasit S., Luanpitpong S., Rojanasakul Y., Nimmannit U. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest: 2009; 27 624 635
24. Yde C. W., Issinger O. G. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol: 2006; 29 1397 1404
25. Brotin E., Meryet-Figuiere M., Simonin K., Duval R. E., Villedieu M., Leroy-Dudal J., Saison-Behmoaras E., Gauduchon P., Denoyelle C., Poulain L. Bcl-x(L) and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer: 2010; 126 885 895
26. Varin E., Denoyelle C., Brotin E., Meryet-Figuiere M., Giffard F., Abeilard E., Goux D., Gauduchon P., Icard P., Poulain L. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis: 2010; 31 984 993
27. Niu G., Wright K. L., Ma Y., Wright G. M., Huang M., Irby R., Briggs J., Karras J., Cress W. D., Pardoll D., Jove R., Chen J., Yu H. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol: 2005; 25 7432 7440 (Pubitemid 41170107)
28. Tang W., Liu J. W., Zhao W. M., Wei D. Z., Zhong J. J. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci: 2006; 80 205 211 (Pubitemid 44853986)
29. Chen N. H., Zhong J. J. p53 is important for the anti-invasion of ganoderic acid T in human carcinoma cells. Phytomedicine: 2011; 18 719 725
30. Chen N. H., Zhong J. J. Ganoderic acid Me induces G1 arrest in wild-type p53 human tumor cells while G1/S transition arrest in p53-null cells. Process Biochem: 2009; 44 928 933
31. Thyagarajan A., Jiang J., Hopf A., Adamec J., Sliva D. Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med: 2006; 18 657 664
32. Chen N. H., Liu J. W., Zhong J. J. Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol Rep: 2010; 62 150 163
33. Wang G., Zhao J., Liu J., Huang Y., Zhong J. J., Tang W. Enhancement of IL-2 and IFN-[gamma] expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. Int Immunopharmacol: 2007; 7 864 870 (Pubitemid 46635284)
34. Pandey M. K., Sung B., Aggarwal B. B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer: 2010; 127 282 292
35. Thoennissen N. H., Iwanski G. B., Doan N. B., Okamoto R., Lin P., Abbassi S., Song J. H., Yin D., Toh M., Xie W. D., Said J. W., Koeffler H. P. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res: 2009; 69 5876 5884
36. Li F., Fernandez P. P., Rajendran P., Hui K. M., Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett: 2010; 292 197 207
37. Pathak A. KR, Bhutani M., Nair A. S., Ahn K. S., Chakraborty A., Kadara H., Guha S., Sethi G., Aggarwal B. B. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res: 2007; 5 943 955 (Pubitemid 47416671)
38. Wu Z. Z., Lu H. P., Chao C. C. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol: 2010; 80 262 276
39. Tam K. H., Yang Z. F., Lau C. K., Lam C. T., Pang R. WC, Poon R. TP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett: 2009; 273 201 209
40. Michaud W. A., Nichols A. C., Mroz E. A., Faquin W. C., Clark J. R., Begum S., Westra W. H., Wada H., Busse P. M., Ellisen L. W., Rocco J. W. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res: 2009; 15 1645 1654
41. Losert D., Pratscher B., Soutschek J., Geick A., Vornlocher H. P., Müller M., Wacheck V. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Anticancer Drugs: 2007; 18 755 761 (Pubitemid 46975961)
42. Liu T., Peng H., Zhang M., Deng Y., Wu Z. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol: 2010; 641 15 22
43. Lau C. K., Yang Z. F., Lam S. P., Lam C. T., Ngai P., Tam K. H., Poon R. T., Fan S. T. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther: 2007; 6 1900 1907 (Pubitemid 351590402)
44. Xi S., Gooding W. E., Grandis J. R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene: 2005; 24 970 979 (Pubitemid 40313874)
45. Song H., Sondak V. K., Barber D. L., Reid T. J., Lin J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol: 2004; 24 1017 1026
46. Turkson J., Zhang S., Mora L. B., Burns A., Sebti S., Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem: 2005; 280 32979 32988 (Pubitemid 41368347)